NEW YORK, August 9, 2017 /PRNewswire/ --
If you want a Stock Review on AXON, AMPE, IMUC, or SYN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Focus is on the Biotech industry, which broadly segments into the medical and agricultural markets. Although enterprising biotechnology is also being applied to other exciting areas like industrial chemical production and bioremediation, the use in these areas is still specialized and limited. Ahead of today's trading session, DailyStockTracker.com takes a closer look at the performances of these four equities: Axovant Sciences Ltd (NYSE: AXON), Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE), ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC), and Synthetic Biologics Inc. (NYSE MKT: SYN). Register now and get full and free access to these DailyStockTracker.com research reports at:
http://dailystocktracker.com/register/
Axovant Sciences
On Tuesday, shares in London, the UK-based Axovant Sciences Ltd recorded a trading volume of 892,430 shares, which was above their three months average volume of 533,110 shares. The stock ended at $23.05, rising 0.70% from the last trading session. The Company's shares have gained 4.30% in the last one month, 0.61% over the previous three months, and 85.59% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.58% and 34.84%, respectively. Furthermore, shares of Axovant Sciences, which engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the US and Europe, have a Relative Strength Index (RSI) of 52.06.
On July 11th, 2017, research firm Jefferies initiated a 'Buy' rating on the Company's stock.
On August 07th, 2017, Axovant Sciences announced financial results for the three months ended June 30th, 2017. R&D expenses for the quarter were $43.7 million, general and administrative expenses were $21.5 million, and net loss was $69.3 million. The Company held cash of $297.9 million at June 30th, 2017. Additionally, net cash used in operating activities was $47.9 million for the three months ended June 30th, 2017. Access our complete research report on AXON for free at:
http://dailystocktracker.com/registration/?symbol=AXON
Ampio Pharma
Englewood, Colorado headquartered Ampio Pharmaceuticals Inc.'s stock finished yesterday's session 1.92% lower at $0.51 with a total trading volume of 322,661 shares. The Company's shares are trading below their 50-day moving average by 11.47%. Shares of the Company, which focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the US, have an RSI of 42.74. The complimentary research report on AMPE can be downloaded at:
http://dailystocktracker.com/registration/?symbol=AMPE
ImmunoCellular Therapeutics
At the close of trading on Tuesday, shares in Calabasas, California-based ImmunoCellular Therapeutics Ltd saw a correction of 1.12%, ending the day at $0.33. The stock recorded a trading volume of 559,127 shares. The Company's shares are trading 61.84% below their 50-day moving average. Moreover, shares of ImmunoCellular Therapeutics, which develops immune-based therapies for the treatment of various cancers, have an RSI of 33.94. Register for free on DailyStockTracker.com and get access to the latest report on IMUC at:
http://dailystocktracker.com/registration/?symbol=IMUC
Synthetic Biologics
Rockville, Maryland headquartered Synthetic Biologics Inc.'s shares ended the day 3.34% higher at $0.61 with a total trading volume of 1.18 million shares. The stock has gained 19.75% in the last month and 32.81% over the previous three months. The Company's shares are trading 4.98% above their 50-day moving average. Additionally, shares of Synthetic Biologics, which develops therapeutics designed to preserve the microbiome to protect and restore the health of patients in the US, have an RSI of 64.63.
On August 03rd, 2017, Synthetic Biologics reported financial results for the three months ended June 30th, 2017. General and administrative expenses had decreased by 23% for Q2 2017 to $1.6 million; R&D expenses had decreased by 33% to $4.8 million; and other income was $2.2 million. Cash and cash equivalents as of June 30th, 2017 remained relatively unchanged at $13.4 million - a small decrease from the prior quarter. Download your free research report on SYN at:
http://dailystocktracker.com/registration/?symbol=SYN
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Advertisement
If you want a Stock Review on AXON, AMPE, IMUC, or SYN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Focus is on the Biotech industry, which broadly segments into the medical and agricultural markets. Although enterprising biotechnology is also being applied to other exciting areas like industrial chemical production and bioremediation, the use in these areas is still specialized and limited. Ahead of today's trading session, DailyStockTracker.com takes a closer look at the performances of these four equities: Axovant Sciences Ltd (NYSE: AXON), Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE), ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC), and Synthetic Biologics Inc. (NYSE MKT: SYN). Register now and get full and free access to these DailyStockTracker.com research reports at:
Advertisement
http://dailystocktracker.com/register/
Axovant Sciences
On Tuesday, shares in London, the UK-based Axovant Sciences Ltd recorded a trading volume of 892,430 shares, which was above their three months average volume of 533,110 shares. The stock ended at $23.05, rising 0.70% from the last trading session. The Company's shares have gained 4.30% in the last one month, 0.61% over the previous three months, and 85.59% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.58% and 34.84%, respectively. Furthermore, shares of Axovant Sciences, which engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the US and Europe, have a Relative Strength Index (RSI) of 52.06.
On July 11th, 2017, research firm Jefferies initiated a 'Buy' rating on the Company's stock.
On August 07th, 2017, Axovant Sciences announced financial results for the three months ended June 30th, 2017. R&D expenses for the quarter were $43.7 million, general and administrative expenses were $21.5 million, and net loss was $69.3 million. The Company held cash of $297.9 million at June 30th, 2017. Additionally, net cash used in operating activities was $47.9 million for the three months ended June 30th, 2017. Access our complete research report on AXON for free at:
http://dailystocktracker.com/registration/?symbol=AXON
Ampio Pharma
Englewood, Colorado headquartered Ampio Pharmaceuticals Inc.'s stock finished yesterday's session 1.92% lower at $0.51 with a total trading volume of 322,661 shares. The Company's shares are trading below their 50-day moving average by 11.47%. Shares of the Company, which focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the US, have an RSI of 42.74. The complimentary research report on AMPE can be downloaded at:
http://dailystocktracker.com/registration/?symbol=AMPE
ImmunoCellular Therapeutics
At the close of trading on Tuesday, shares in Calabasas, California-based ImmunoCellular Therapeutics Ltd saw a correction of 1.12%, ending the day at $0.33. The stock recorded a trading volume of 559,127 shares. The Company's shares are trading 61.84% below their 50-day moving average. Moreover, shares of ImmunoCellular Therapeutics, which develops immune-based therapies for the treatment of various cancers, have an RSI of 33.94. Register for free on DailyStockTracker.com and get access to the latest report on IMUC at:
http://dailystocktracker.com/registration/?symbol=IMUC
Synthetic Biologics
Rockville, Maryland headquartered Synthetic Biologics Inc.'s shares ended the day 3.34% higher at $0.61 with a total trading volume of 1.18 million shares. The stock has gained 19.75% in the last month and 32.81% over the previous three months. The Company's shares are trading 4.98% above their 50-day moving average. Additionally, shares of Synthetic Biologics, which develops therapeutics designed to preserve the microbiome to protect and restore the health of patients in the US, have an RSI of 64.63.
On August 03rd, 2017, Synthetic Biologics reported financial results for the three months ended June 30th, 2017. General and administrative expenses had decreased by 23% for Q2 2017 to $1.6 million; R&D expenses had decreased by 33% to $4.8 million; and other income was $2.2 million. Cash and cash equivalents as of June 30th, 2017 remained relatively unchanged at $13.4 million - a small decrease from the prior quarter. Download your free research report on SYN at:
http://dailystocktracker.com/registration/?symbol=SYN
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
